Abstract
Reinfusion of undetected tumour cells is a possible cause of relapse after autologous bone-marrow transplantation. In this paper, a system for in-vitro purging of bone marrow is presented which involves the B-cell neoplasia-associated monoclonal antibody anti-Y 29/55 and complement. Five patients with Burkitt's lymphoma were transplanted with purged marrow, demonstrating the clinical feasibility of the method. The pretransplant regimen included vincristine 2 mg/m2, adriamycin 60 mg/m2, four doses of cyclophosphamide 45 mg/kg and total body irradiation with 6 Gy. Tumour control appears to be better in patients with purged bone marrow as compared to an earlier patient group with unpurged marrow.
Publication types
-
Clinical Trial
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Antibodies, Monoclonal / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bone Marrow / pathology
-
Bone Marrow Transplantation*
-
Burkitt Lymphoma / drug therapy
-
Burkitt Lymphoma / radiotherapy
-
Burkitt Lymphoma / therapy*
-
Clinical Trials as Topic
-
Combined Modality Therapy
-
Complement System Proteins*
-
Cyclophosphamide / administration & dosage
-
Doxorubicin / administration & dosage
-
Humans
-
Male
-
Transplantation, Autologous
-
Vincristine / administration & dosage
Substances
-
Antibodies, Monoclonal
-
Vincristine
-
Doxorubicin
-
Cyclophosphamide
-
Complement System Proteins